Allergic and Immunologic Conditions

Targeting IL-36 signaling, imsidolimab significantly improved clear or almost clear skin responses at Week 4 compared with placebo in patients experiencing a generalized pustular psoriasis flare, with monthly maintenance treatment supporting sustained responses through 24 weeks.

Join us as leading experts discuss key data and perspectives from the late-breaking sessions at this year’s AAD meeting This March, experts from around the world gathered in Denver, Colorado, for the 2026 American Academy of Dermatology (AAD) Annual Meeting. ...

Founded by internationally recognised experts the IDS meeting brings together world leaders working across immune-activated skin conditions such as psoriasis, atopic dermatitis, alopecia areata, vitiligo and hidradenitis suppurativa. To capture key perspectives from the 2025 Summit, we spoke with editorial board member, Prof. Dedee Murrell, to bring you some of the key highlights from a selection of standout presentations delivered during the three-day event.

As 2025 draws to a close, it is clear that the past year has brought notable shifts across dermatology. To reflect on the developments that stood out most, members of our editorial board and recipients of our 2025 Future Leaders in Dermatology award share their perspectives, drawing on experience across subspecialties, regions and stages of career.

Early phase pooled results from 32 patients indicate that lonvoguran ziclumeran, a CRISPR-based gene-editing therapy, achieved durable, one-time disease control in hereditary angioedema (HAE). The phase 1/2 data demonstrated deep and sustained reductions in plasma kallikrein levels, with most patients remaining attack-free and prophylaxis-free for up to three years and a safety profile consistent with earlier findings.

Remibrutinib is a recently approved oral Bruton’s tyrosine kinase (BTK) inhibitor for CSU that has shown superior efficacy over placebo and a favourable safety profile in the pivotal phase 3 REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) trials. By inhibiting BTK, a central mediator of B-cell signalling and autoantibody production, remibrutinib may not only provide symptom relief and improves quality of life for patients with CSU, but could potentially modify the underlying disease mechanisms in autoantibody-positive patients and influence the long-term course of the condition. At the EADV Congress 2025, we had the pleasure of speaking with Prof. Martin Metz (Berlin, Germany), who presented new data on the immunomodulatory effects of remibrutinib. In our interview, Prof. Metz discusses the latest insights, explores how these findings could shape future clinical practice and reflects on the key questions that remain as research in this area continues to evolve.

Watch four dermatology experts explore the evolving science of type 2 inflammation in a series of videos originally presented at the March 2025 ADVENT symposium in Orlando, Florida.

In this episode, we speak with leading paediatric allergist Prof. Helen Brough to explore the key factors behind why some children develop allergies to foods such as peanuts, and what we can do to help prevent them. We also examine the latest developments in managing food allergies and the innovations on the horizon that could transform how we treat them.

This year, we are celebrating our inaugural touchDERMATOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform dermatology in the years to come. Representing a diverse range of expertise from across the globe, these highly accomplished clinicians are among the brightest minds shaping the future of dermatology. We had the pleasure of learning about their unique career journeys, motivations, and the inspirations that have guided their paths. They also shared their perspectives on the most exciting developments in dermatology today, along with their hopes for the future of the field. Congratulations to all our touchDERMATOLOGY Future Leaders, and thank you for sharing your stories, insights and ambitions with us.